Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.5200+0.0900 (+2.62%)
At close: 04:00PM EDT
3.6200 +0.10 (+2.84%)
After hours: 05:33PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 400.69M
Enterprise value 119.22M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)53.89
Price/book (mrq)0.94
Enterprise value/revenue 18.40
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.80
52-week change 3-29.03%
S&P500 52-week change 326.14%
52-week high 38.8300
52-week low 31.6300
50-day moving average 35.2788
200-day moving average 34.0511

Share statistics

Avg vol (3-month) 32.61M
Avg vol (10-day) 31.95M
Shares outstanding 5113.83M
Implied shares outstanding 6113.83M
Float 890.48M
% held by insiders 11.58%
% held by institutions 1109.64%
Shares short (30 Apr 2024) 422.14M
Short ratio (30 Apr 2024) 49.26
Short % of float (30 Apr 2024) 422.32%
Short % of shares outstanding (30 Apr 2024) 419.45%
Shares short (prior month 28 Mar 2024) 416.49M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-2,652.88%

Management effectiveness

Return on assets (ttm)-20.84%
Return on equity (ttm)-42.07%

Income statement

Revenue (ttm)6.48M
Revenue per share (ttm)0.06
Quarterly revenue growth (yoy)-96.70%
Gross profit (ttm)N/A
EBITDA -181.18M
Net income avi to common (ttm)-190.05M
Diluted EPS (ttm)-1.9200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)383.54M
Total cash per share (mrq)3.37
Total debt (mrq)102.07M
Total debt/equity (mrq)23.95%
Current ratio (mrq)8.69
Book value per share (mrq)3.74

Cash flow statement

Operating cash flow (ttm)-136.75M
Levered free cash flow (ttm)-51.7M